<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687466</url>
  </required_header>
  <id_info>
    <org_study_id>FFC #21/2006</org_study_id>
    <secondary_id>eudraCT number 2005-002135-27</secondary_id>
    <secondary_id>IGG-FC-G-01</secondary_id>
    <nct_id>NCT00687466</nct_id>
  </id_info>
  <brief_title>Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay</brief_title>
  <official_title>Phase 3 Study on the Efficacy of Slow Release Insulin in Cystic Fibrosis Patients With Glucide Intolerance and Clinical Decay</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione per la ricerca sulla Fibrosi Cistica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione per la ricerca sulla Fibrosi Cistica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the anticipated use of glargine in CF
      patients with glucose intolerance may prevent the worsening of nutritional status and
      pulmonary function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus may often complicate the cystic fibrosis course, and it is usually preceded
      by a condition defined as glucose intolerance, during which a significant decay of patient's
      general conditions is observed. A slow release insulin (glargine) has become available in the
      market for diabetic patients: its characteristics allow for a single daily dose, and no need
      of repeated daily monitoring of glycemia.

      In this randomized controlled clinical trial we evaluate whether the anticipated use of
      glargine in CF patients with glucose intolerance may prevent the worsening of nutritional
      status and pulmonary function.

      Eligible patients who will accept to participate to this study will be randomly allocated in
      the group who will or will not receive glargine as additional supportive therapy. Patients
      will in any case continue the CF therapy prescribed by their treating physicians and their
      usual diet. All the patients will be evaluated every three months to assess their
      nutritional, pulmonary and glycometabolic status. The follow-up will continue until the 18th
      month after the study entry.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">October 2009</completion_date>
  <primary_completion_date type="Anticipated">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional status evaluated as variations of Z score of BMI</measure>
    <time_frame>At recruitment time and at +3, +6, +9, +12, +15, +18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance improvement evaluated as improvement of glycometabolic parameter (glycosylated Hb)</measure>
    <time_frame>At time recruitment and +3,+6,+9+12+15+18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Glucose Intolerance</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin yes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Insulin no</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.
Glargine should be administered once daily in the morning and always at the same hour.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ascertained diagnosis of CF

          -  Age ≥ 10 years

          -  Glucide intolerance: 2 pathologic OGTT ( at 120' glucose value: &gt;140 mg% and &lt;200 mg%)
             at 2-6 months' interval between each other

          -  At least one of the following conditions:

               -  BMI (body mass index) &lt; 10th centile for age and sex (according to Rolland
                  Cachera 1991)

               -  Loss of one BMI centile class for age and sex in the last year (according to
                  Rolland Cachera 1991)

               -  FEV1 ≤ 80% of predicted

               -  FEV1 decrease ≥ 10% in the last year

        Exclusion Criteria:

          -  Specific contraindications for the use of glargine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Minicucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>G.Gaslini Institute Pediatric Department CF Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pediatric Department, General Hospital,CF Center</name>
      <address>
        <city>Cerignola (Foggia)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore Policlinico, Adult CF Center</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Department, Federico II University, Pediatric CF Center</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Department G.De Cristina Hospital CF Center</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Hospital CF Center</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I. CF Center</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Moran A, Hardin D, Rodman D, Allen HF, Beall RJ, Borowitz D, Brunzell C, Campbell PW 3rd, Chesrown SE, Duchow C, Fink RJ, Fitzsimmons SC, Hamilton N, Hirsch I, Howenstine MS, Klein DJ, Madhun Z, Pencharz PB, Quittner AL, Robbins MK, Schindler T, Schissel K, Schwarzenberg SJ, Stallings VA, Zipf WB, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract. 1999 Aug;45(1):61-73. Review.</citation>
    <PMID>10499886</PMID>
  </reference>
  <reference>
    <citation>Mackie AD, Thornton SJ, Edenborough FP. Cystic fibrosis-related diabetes. Diabet Med. 2003 Jun;20(6):425-36. Review.</citation>
    <PMID>12786675</PMID>
  </reference>
  <reference>
    <citation>Solomon MP, Wilson DC, Corey M, Kalnins D, Zielenski J, Tsui LC, Pencharz P, Durie P, Sweezey NB. Glucose intolerance in children with cystic fibrosis. J Pediatr. 2003 Feb;142(2):128-32.</citation>
    <PMID>12584532</PMID>
  </reference>
  <reference>
    <citation>Lanng S, Thorsteinsson B, Nerup J, Koch C. Influence of the development of diabetes mellitus on clinical status in patients with cystic fibrosis. Eur J Pediatr. 1992 Sep;151(9):684-7.</citation>
    <PMID>1396931</PMID>
  </reference>
  <reference>
    <citation>Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):891-5.</citation>
    <PMID>10988101</PMID>
  </reference>
  <reference>
    <citation>Dobson L, Hattersley AT, Tiley S, Elworthy S, Oades PJ, Sheldon CD. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child. 2002 Nov;87(5):430-1.</citation>
    <PMID>12390923</PMID>
  </reference>
  <reference>
    <citation>Rafii M, Chapman K, Stewart C, Kelly E, Hanna A, Wilson DC, Tullis E, Pencharz PB. Changes in response to insulin and the effects of varying glucose tolerance on whole-body protein metabolism in patients with cystic fibrosis. Am J Clin Nutr. 2005 Feb;81(2):421-6.</citation>
    <PMID>15699230</PMID>
  </reference>
  <reference>
    <citation>Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N, Czernichow P, Polak M. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr. 2001 Aug;90(8):860-7.</citation>
    <PMID>11529531</PMID>
  </reference>
  <reference>
    <citation>Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin improves clinical status of patients with cystic-fibrosis-related diabetes mellitus. Acta Paediatr. 2001 May;90(5):515-9.</citation>
    <PMID>11430710</PMID>
  </reference>
  <reference>
    <citation>Dobson L, Sheldon CD, Hattersley AT. Conventional measures underestimate glycaemia in cystic fibrosis patients. Diabet Med. 2004 Jul;21(7):691-6.</citation>
    <PMID>15209760</PMID>
  </reference>
  <reference>
    <citation>Lombardo F, De Luca F, Rosano M, Sferlazzas C, Lucanto C, Arrigo T, Messina MF, Crisafulli G, Wasniewska M, Valenzise M, Cucinotta D. Natural history of glucose tolerance, beta-cell function and peripheral insulin sensitivity in cystic fibrosis patients with fasting euglycemia. Eur J Endocrinol. 2003 Jul;149(1):53-9.</citation>
    <PMID>12824866</PMID>
  </reference>
  <reference>
    <citation>Bizzarri C, Lucidi V, Ciampalini P, Bella S, Russo B, Cappa M. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest. 2006 Mar;29(3):RC1-4.</citation>
    <PMID>16682829</PMID>
  </reference>
  <reference>
    <citation>Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, Grasset E, Sermet I, de Blic J, Lenoir G, Robert JJ. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008 Apr;152(4):540-5, 545.e1. doi: 10.1016/j.jpeds.2007.09.025. Epub 2007 Nov 26.</citation>
    <PMID>18346512</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 27, 2008</study_first_submitted>
  <study_first_submitted_qc>May 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <last_update_submitted>August 3, 2009</last_update_submitted>
  <last_update_submitted_qc>August 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2009</last_update_posted>
  <responsible_party>
    <name_title>Laura Minicucci. MD, Genova CF Center Head</name_title>
    <organization>Pediatric Department,CF Center Genova, G.Gaslini Institute, Genova, Italy</organization>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Glucose Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

